Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT)

Historical Holders from Q1 2023 to Q3 2025

Symbol
IKT on Nasdaq
CUSIP
45719W205
Type / Class
Equity / Common Stock, $0.001 par value
Shares outstanding
78.2M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
55M
Holdings value
$89M
% of all portfolios
0%
Grand Portfolio weight change
+0%
Number of holders
53
Number of buys
22
Number of sells
-17
Average Value change %
+0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Sands Capital Life Sciences Pulse Fund II, L.P. 14.7% $18.4M 11M Sands Capital Life Sciences Pulse Fund II, L.P. Jun 30, 2025
ADAR1 Capital Management, LLC 9.9% -0.9% $13M $1.25M 7.74M +10.6% ADAR1 Capital Management GP, LLC Jun 30, 2025
Fairmount Funds Management LLC 9.9% $15.3M 7.02M Fairmount Funds Management LLC Dec 31, 2024
Nantahala Capital Management, LLC 7.54% $11.6M 5.3M Nantahala Capital Management, LLC Dec 31, 2024
ARMISTICE CAPITAL, LLC 4.99% $7.69M 3.53M Armistice Capital, LLC Dec 31, 2024

Institutional Holders of Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 55M $89M +$713K $1.62 53
2025 Q2 54.5M $106M +$5.48M $1.95 48
2025 Q1 51.5M $113M +$3.03M $2.19 47
2024 Q4 50.1M $163M +$161M $3.25 31
2024 Q3 860K $1.12M +$30.2K $1.30 11
2024 Q2 836K $1.02M +$723K $1.21 12
2024 Q1 206K $444K -$62.2K $2.16 12
2023 Q4 235K $299K -$271K $1.27 11
2023 Q3 430K $598K -$497K $1.39 13
2023 Q2 747K $2.69M +$2.39M $3.61 14
2023 Q1 82.8K $54.5K +$54.5K $0.66 1